Cargando…

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer

BACKGROUND: The impact of neoadjuvant chemoimmunotherapy on pulmonary resection and related outcomes had been poorly reported in previous studies. The present study aims to clarify the efficacy and safety of neoadjuvant chemoimmunotherapy, and intraoperative difficulty in the following surgery, in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Baihua, Xiao, Haifan, Pu, Xingxiang, Zhou, Chunhua, Yang, Desong, Li, Xu, Wang, Wenxiang, Xiao, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844597/ https://www.ncbi.nlm.nih.gov/pubmed/35621048 http://dx.doi.org/10.1002/cam4.4889

Ejemplares similares

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis
por: Zhang, Baihua, et al.
Publicado: (2023)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
por: Lu, Meng, et al.
Publicado: (2022)

A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
por: Liu, Wei, et al.
Publicado: (2022)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study
por: Liu, Wenliang, et al.
Publicado: (2023)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Spindle cell carcinoma of the esophagus: A multicenter analysis in comparison with typical squamous cell carcinoma
por: Zhang, Baihua, et al.
Publicado: (2016)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer
por: Han, Rui, et al.
Publicado: (2023)

Organ preservation strategies after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a multicenter retrospective cohort study
por: Hui, Bengang, et al.
Publicado: (2023)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Primary small cell carcinoma of the esophagus: Comparison between a Chinese cohort and Surveillance, Epidemiology, and End Results (SEER) data
por: Xiao, Qin, et al.
Publicado: (2019)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
por: Jiang, Juan, et al.
Publicado: (2022)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
por: Tuminello, Stephanie, et al.
Publicado: (2022)

Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
por: Zhao, Deping, et al.
Publicado: (2022)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy vesus Chemotherapy alone Followed by Surgery for Resectable Stage III Non-Small-Cell Lung Cancer: a Meta-Analysis
por: Guo, Shan xian, et al.
Publicado: (2016)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Erratum: Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Publicado: (2023)

Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis
por: Zhu, Qunying, et al.
Publicado: (2023)

Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients
por: Li, Zhensheng, et al.
Publicado: (2023)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
por: Takada, Kazuki, et al.
Publicado: (2023)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features
por: Yang, Nong, et al.
Publicado: (2023)

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study
por: She, Yunlang, et al.
Publicado: (2022)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4epahh3695hl4s7gfjitv9ll4o